QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
NASDAQ:ALIM

Alimera Sciences (ALIM) Stock Forecast, Price & News

$3.21
+0.20 (+6.64%)
(As of 09/26/2023 ET)
Compare
Today's Range
$2.94
$3.24
50-Day Range
$3.01
$3.80
52-Week Range
$1.30
$6.25
Volume
70,139 shs
Average Volume
236,584 shs
Market Capitalization
$28.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.83

Alimera Sciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
81.7% Upside
$5.83 Price Target
Short Interest
Healthy
3.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Alimera Sciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$1.96 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.01) to $0.39 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

356th out of 964 stocks

Pharmaceutical Preparations Industry

151st out of 445 stocks


ALIM stock logo

About Alimera Sciences (NASDAQ:ALIM) Stock

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals. It operates through United States, internationally, and Operating Cost segments. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, clinics, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

ALIM Price History

ALIM Stock News Headlines

Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Alimera Sciences, Inc.'s (NASDAQ:ALIM) Profit Outlook
The Latest Analyst Ratings for Alimera Sciences
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Q2 2023 Alimera Sciences Inc Earnings Call
Alimera Sciences Reports Second Quarter 2023 Results
Preview: Alimera Sciences's Earnings
Expert Ratings for Alimera Sciences
See More Headlines
Receive ALIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter.

ALIM Company Calendar

Last Earnings
8/10/2023
Today
9/26/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALIM
Employees
150
Year Founded
2003

Price Target and Rating

Average Stock Price Forecast
$5.83
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$4.50
Forecasted Upside/Downside
+81.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-18,110,000.00
Pretax Margin
-40.88%

Debt

Sales & Book Value

Annual Sales
$54.13 million
Book Value
($5.72) per share

Miscellaneous

Free Float
6,038,000
Market Cap
$28.25 million
Optionable
Optionable
Beta
1.40

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Richard S. Eiswirth Jr.Mr. Richard S. Eiswirth Jr. (Age 55)
    Pres, CEO & Director
    Comp: $597.87k
  • Mr. David R. Holland (Age 59)
    Co-Founder, Chief Marketing Officer and Sr. VP of Corp. Communications & Managed Markets
    Comp: $413.5k
  • Dr. Philip Ashman Ph.D. (Age 58)
    COO & Sr. VP of Commercial Operations - Europe
    Comp: $389.86k
  • Mr. Russell L. Skibsted M.B.A. (Age 64)
    Sr. VP & CFO
  • Christopher S. Visick
    VP, Gen. Counsel & Sec.
  • Dr. David Dyer M.D.
    Chief Retina Specialist













ALIM Stock - Frequently Asked Questions

Should I buy or sell Alimera Sciences stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALIM shares.
View ALIM analyst ratings
or view top-rated stocks.

What is Alimera Sciences' stock price forecast for 2023?

2 equities research analysts have issued 12-month target prices for Alimera Sciences' shares. Their ALIM share price forecasts range from $4.50 to $8.00. On average, they anticipate the company's share price to reach $5.83 in the next twelve months. This suggests a possible upside of 81.7% from the stock's current price.
View analysts price targets for ALIM
or view top-rated stocks among Wall Street analysts.

How have ALIM shares performed in 2023?

Alimera Sciences' stock was trading at $2.71 at the beginning of 2023. Since then, ALIM stock has increased by 18.5% and is now trading at $3.21.
View the best growth stocks for 2023 here
.

Are investors shorting Alimera Sciences?

Alimera Sciences saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 121,700 shares, a drop of 82.5% from the August 15th total of 697,400 shares. Based on an average daily trading volume, of 43,000 shares, the short-interest ratio is presently 2.8 days. Currently, 3.1% of the shares of the stock are sold short.
View Alimera Sciences' Short Interest
.

When is Alimera Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ALIM earnings forecast
.

How were Alimera Sciences' earnings last quarter?

Alimera Sciences, Inc. (NASDAQ:ALIM) issued its quarterly earnings results on Thursday, August, 10th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of $0.06 by $0.50. The biopharmaceutical company had revenue of $17.54 million for the quarter, compared to analysts' expectations of $20.36 million.

When did Alimera Sciences' stock split?

Alimera Sciences's stock reverse split before market open on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is Rick Eiswirth's approval rating as Alimera Sciences' CEO?

2 employees have rated Alimera Sciences Chief Executive Officer Rick Eiswirth on Glassdoor.com. Rick Eiswirth has an approval rating of 100% among the company's employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alimera Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN), AngloGold Ashanti (AU), SSR Mining (SSRM), ADMA Biologics (ADMA) and Cellectar Biosciences (CLRB).

What is Alimera Sciences' stock symbol?

Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."

Who are Alimera Sciences' major shareholders?

Alimera Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Velan Capital Investment Management LP (18.84%), Renaissance Technologies LLC (1.47%), Geode Capital Management LLC (0.67%), Osaic Holdings Inc. (0.13%), Osaic Holdings Inc. (0.13%) and Perritt Capital Management Inc. (0.11%). Insiders that own company stock include Adam Morgan, Alto Investors Lp Palo, Caligan Partners Lp, James R Largent, John Philip Jones, Philip Ashman, Richard S Eiswirth Jr and Stanley Morgan.
View institutional ownership trends
.

How do I buy shares of Alimera Sciences?

Shares of ALIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alimera Sciences' stock price today?

One share of ALIM stock can currently be purchased for approximately $3.21.

How much money does Alimera Sciences make?

Alimera Sciences (NASDAQ:ALIM) has a market capitalization of $28.25 million and generates $54.13 million in revenue each year. The biopharmaceutical company earns $-18,110,000.00 in net income (profit) each year or ($3.32) on an earnings per share basis.

How many employees does Alimera Sciences have?

The company employs 150 workers across the globe.

How can I contact Alimera Sciences?

Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The official website for the company is www.alimerasciences.com. The biopharmaceutical company can be reached via phone at (678) 990-5740, via email at scottg@coreir.com, or via fax at 678-990-5744.

This page (NASDAQ:ALIM) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -